Literature DB >> 22621634

Ruxolitinib for myelofibrosis.

Steffen Koschmieder, Adriane Koppelle, Hans Seifert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22621634     DOI： 10.1056/NEJMc1203704

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.

Authors:  Matthew Yan; Holly Geyer; Ruben Mesa; Ehab Atallah; Jeannie Callum; Justyna Bartoszko; Karen Yee; Manjula Maganti; Florence Wong; Vikas Gupta
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-11

Review 2.  Practical management of patients with myelofibrosis receiving ruxolitinib.

Authors:  Claire Harrison; Ruben Mesa; David Ross; Adam Mead; Clodagh Keohane; Jason Gotlib; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2013-10-02       Impact factor: 2.929

3.  Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome.

Authors:  Bruno Deltreggia Benites; Carolina Silva Costa Lima; Irene Lorand-Metze; Marcia Torresan Delamain; Gislaine Borba Oliveira; Daiane de Almeida; Carmino Antonio de Souza; Jose Vassallo; Katia Borgia Barbosa Pagnano
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.